Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?

Pancreatic resection still represents the only curative option for patients affected by pancreatic ductal adenocarcinoma (PDAC). However, the association with modern chemotherapy regimens is a key factor in improving the inauspicious oncological outcome. The benefit of neoadjuvant treatment (NAT) fo...

Full description

Bibliographic Details
Main Authors: Marco Vivarelli, Federico Mocchegiani, Daniele Nicolini, Andrea Vecchi, Grazia Conte, Enrico Dalla Bona, Roberta Rossi, Andrea Benedetti Cacciaguerra
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
pancreatic adenocarcinoma
resectable pancreatic adenocarcinoma
neoadjuvant treatment
chemotherapy
upfront surgery
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.914203/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.914203/full

Similar Items